Same Indication

Montelukast vs Tofacitinib

Montelukast vs Tofacitinib: Overview

This comparison examines the pharmacological differences between Montelukast and Tofacitinib.

Mechanism of Action

Montelukast: Selective leukotriene D4 receptor antagonist.

Tofacitinib: Pan-JAK inhibitor with preference for JAK1 and JAK3 blocking pro-inflammatory cytokine signaling.

Pharmacokinetics

Half-life: Montelukast — 2.7-5.5 hours; Tofacitinib — 3.2 hours.

Chemical Properties

Molecular Formula: Montelukast — C35H36ClNO3S; Tofacitinib — C16H20N6O.

Molecular Weight: Montelukast — 586.1800 g/mol; Tofacitinib — 312.3700 g/mol.

Type: Montelukast — Small molecule; Tofacitinib — Small molecule.